279 related articles for article (PubMed ID: 29656435)
1. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.
Shen S; Zhang R; Guo Y; Loehrer E; Wei Y; Zhu Y; Yuan Q; Moran S; Fleischer T; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Su L; Chen F; Christiani DC
Mol Oncol; 2018 Jun; 12(6):913-924. PubMed ID: 29656435
[TBL] [Abstract][Full Text] [Related]
2. miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression.
He Z; Liu Y; Xiao B; Qian X
Biochem Biophys Res Commun; 2015 Feb; 457(3):235-41. PubMed ID: 25576360
[TBL] [Abstract][Full Text] [Related]
3. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
4. Elevated BTG2 improves the radiosensitivity of non-small cell lung cancer (NSCLC) through apoptosis.
Zhu C; Zhang S; Xue A; Feng G; Fan S
Thorac Cancer; 2022 May; 13(10):1441-1448. PubMed ID: 35388633
[TBL] [Abstract][Full Text] [Related]
5. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
6. Methylation markers of early-stage non-small cell lung cancer.
Lokk K; Vooder T; Kolde R; Välk K; Võsa U; Roosipuu R; Milani L; Fischer K; Koltsina M; Urgard E; Annilo T; Metspalu A; Tõnisson N
PLoS One; 2012; 7(6):e39813. PubMed ID: 22768131
[TBL] [Abstract][Full Text] [Related]
7. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
[TBL] [Abstract][Full Text] [Related]
8. miR-663 sustains NSCLC by inhibiting mitochondrial outer membrane permeabilization (MOMP) through PUMA/BBC3 and BTG2.
Fiori ME; Villanova L; Barbini C; De Angelis ML; De Maria R
Cell Death Dis; 2018 Jan; 9(2):49. PubMed ID: 29352138
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation of
Guo Y; Zhang R; Shen S; Wei Y; Salama SM; Fleischer T; Bjaanæs MM; Karlsson A; Planck M; Su L; Zhu Z; Staaf J; Helland Å; Esteller M; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1527-1535. PubMed ID: 30185536
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
11. EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.
Zhang R; Lai L; He J; Chen C; You D; Duan W; Dong X; Zhu Y; Lin L; Shen S; Guo Y; Su L; Shafer A; Moran S; Fleischer T; Bjaanæs MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
Epigenetics; 2019 Feb; 14(2):118-129. PubMed ID: 30665327
[TBL] [Abstract][Full Text] [Related]
12. LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression.
Wu A; Li J; Wu K; Mo Y; Luo Y; Ye H; Mai Z; Guo K; Wang Y; Li S; Chen H; Luo W; Yang Z
Biomed Pharmacother; 2016 Aug; 82():290-7. PubMed ID: 27470365
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
14. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients.
Ji X; Lin L; Shen S; Dong X; Chen C; Li Y; Zhu Y; Huang H; Chen J; Chen X; Wei L; He J; Duan W; Su L; Jiang Y; Fan J; Guan J; You D; Shafer A; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Wei Y; Zhang R; Chen F; Christiani DC
Mol Oncol; 2020 Nov; 14(11):2759-2774. PubMed ID: 33448640
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
Wang M; Li P; Wan R; Liu X
Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
[TBL] [Abstract][Full Text] [Related]
17. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
18. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
Gentles AJ; Bratman SV; Lee LJ; Harris JP; Feng W; Nair RV; Shultz DB; Nair VS; Hoang CD; West RB; Plevritis SK; Alizadeh AA; Diehn M
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26286589
[TBL] [Abstract][Full Text] [Related]
19. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
20. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
